Beta Bionics (BBNX) CFO Executes 10b5-1 Sale After $5.10 Option Exercise

Rhea-AI Filing Summary

Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (BBNX), reported insider transactions on 08/19/2025. He acquired 5,587 shares via an employee stock option with an exercise price of $5.10 and immediately sold 5,587 shares pursuant to a Rule 10b5-1 plan at a weighted average price of $17.034505 (price range $17.00–$17.095). After these transactions his direct beneficial ownership decreased from 51,090 shares to 45,503 shares. The option shares vest in 48 equal monthly installments measured from September 14, 2023, and the related option lists an exercisable/expiration reference dated 09/13/2033.

Positive

• Sale executed under a Rule 10b5-1 plan, indicating the disposition was pre-planned and compliant with insider trading rules
• Exercise/acquisition at $5.10 strike with sale at a much higher weighted average price ($17.034505), generating a realized gain for the reporting person
• Clear vesting schedule disclosed (48 equal monthly installments from 09/14/2023), improving transparency on future insider equity availability

Negative

• Direct holdings reduced from 51,090 shares to 45,503 shares after the reported sale, a material reduction of the reporting person's direct stake
• Potential dilution if option exercises result in new share issuance (options underlying 104,108 reported), which could affect outstanding share count if exercised

Insights

Financial Analyst

TL;DR: CFO executed an option acquisition at a low strike and sold the same number of shares under a 10b5-1 plan, reducing direct holdings modestly.

Feider exercised or was granted rights to 5,587 shares at a $5.10 price and sold 5,587 shares under a pre-established Rule 10b5-1 plan at a weighted average of $17.0345. The transactions are cash-positive for the reporting person and dilutive only to the extent of option exercises when shares are issued, but here the sale appears to be from shares sold under the plan. The reduction in direct holdings from 51,090 to 45,503 represents a meaningful but not large percentage of his direct stake.

Corporate Governance Expert

TL;DR: Transactions follow a formal 10b5-1 plan, indicating pre-planned disposition rather than ad hoc insider selling.

The sale is explicitly reported as pursuant to a Rule 10b5-1 plan adopted May 15, 2025, which provides affirmative defense from insider trading claims. That procedural compliance is important for governance and disclosure standards. Vesting terms (48 monthly installments from 09/14/2023) are disclosed, supporting transparency about how additional equity will become available to the officer over time.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Feider Stephen

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/19/2025		M		5,587	A	$5.1	51,090	D
Common Stock	08/19/2025		S(1)		5,587	D	$17.0345(2)	45,503	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$5.1	08/19/2025		M			5,587	(3)	09/13/2033	Common Stock	5,587	$0	104,108	D

Explanation of Responses:

1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025.

2. The weighted average sale price for the transaction reported was $17.034505 and the range of prices were between $17.00 and $17.095. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

3. The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.

	/s/ Stephen Feider	08/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Beta Bionics (BBNX) CFO Stephen Feider report on Form 4?

He reported acquiring 5,587 shares via an employee stock option at $5.10 and selling 5,587 shares on 08/19/2025 pursuant to a Rule 10b5-1 plan at a weighted average price of $17.034505.

Were the sales by the insider pre-planned or ad hoc?

The sales were executed pursuant to a Rule 10b5-1 plan adopted May 15, 2025, indicating the transactions were pre-planned.

How did these transactions change Stephen Feider’s shareholdings in BBNX?

His direct beneficial ownership decreased from 51,090 shares to 45,503 shares after the reported sale of 5,587 shares.

What price range and weighted average price were reported for the sale?

The sale price ranged between $17.00 and $17.095 with a weighted average sale price of $17.034505.

What are the vesting terms for the option shares?

The shares subject to the option vest in 48 equal monthly installments measured from September 14, 2023.